Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose ...
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
The Zepbound LillyDirect offers comes in a single-dose vial rather than as an auto-injector pen, also called a Zepbound pen. The vial doses available are 2.5 mg and 5 mg, which is limited compared ...
When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback